Nuvaxovid Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

SARS-CoV-2 recombinant spike protein (Omicron JN.1)

Indications/Uses

Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals ≥12 yr.

Dosage/Direction for Use

IM Individual ≥12 yr Primary vaccination series: 2 doses of 0.5 mL each. Administer 2nd dose 3 wk after 1st dose. Booster dose: Administer at least 3 mth after most recent COVID-19 vaccine dose.

Contraindications

Hypersensitivity.

MIMS Class

Vaccines, Antisera & Immunologicals

ATC Classification

J07BN04 - covid-19, protein subunit ; Belongs to the class of covid-19 vaccines.

Regulatory Classification

POM

Presentation/Packing

Form

Nuvaxovid dispersion for inj 5 mcg/0.5mL

Packing/Price

1's

Nuvaxovid

Manufacturer:

Siegfried Hameln